Status:
COMPLETED
Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery
Lead Sponsor:
Yonsei University
Conditions:
Coronary Artery
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Trimetazidine is a metabolic agent without any negative inotropic or vasodilatory properties. In addition, previous reports showed that trimetazidine was effective in reducing intracoronary platelet a...
Eligibility Criteria
Inclusion
- Patients who had previously received CABG 12 months ago
- Patients who were free of death, MI or repeat revascularization within first 12 months after CABG
- Patients with mono antiplatelet therapy with aspirin alone
- Age of 20 years or older
- Patients with signed informed consent
Exclusion
- History of DES or BMS implantation within 12 months
- Patients who required the continuing dual antiplatelet therapy or additional other types of antithrombotics or antiplatelets such as cilostazol or ticlopidine, etc besides aspirin after DES implantation
- Patients who could not be prescribed aspirin or statins due to contraindication or severe side effects
- Pregnant women or women with potential childbearing
- Life expectancy ≤ 2 year
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2018
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT01857921
Start Date
December 1 2010
End Date
April 8 2018
Last Update
March 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, South Korea, 120-752